Once-daily gentamicin administration for community-associated methicillin resistant Staphylococcus aureus in an in vitro pharmacodynamic model: preliminary reports for the advantages for optimizing pharmacodynamic index.

Yonsei Medical Journal
Sun Woo KimWan-Shik Shin

Abstract

Community-associated methicillin resistant Staphylococcus aureus (CAMRSA) infections are increasing. Although gentamicin (GEN) is usually susceptible against CA-MRSA, GEN is rarely considered for treatment as monotherapy. We employed an in vitro pharmacodynamic model (IVPDM) to compare efficacies of GEN against CA-MRSA with two dosing regimens [thrice-daily (TD), once-daily (OD)]. Using two strains of CA-MRSA, we adopted IVPDM comprised of two-compartments with a surface-to-volume ratio of 5.34 cm(-1). GEN regimens were simulated with human pharmacokinetic data of TD and OD. Experiments were performed over 48 hours in triplicate for each strain and dosing regimen. MICs of GEN for YSSA1 and YSSA15 were 1 and 2 mg/L, respectively. In OD, indices of peak/MIC were > 8.6 at least, in contrast to < 6.4 in TD. A > or = 3-log(10) reduction in CFU/mL was demonstrated prior to 4 hours in TD and OD, and continued until 8 hours for both strains. However, reductions in the colony counts at 24 and 48 hours were significantly larger for OD compared to TD in both strains (p < 0.001). During TD, resistance developed in YSSA1 and small colony variants (SCVs) were documented in YSSA15. No resistance or SCVs were observed during OD in both strains...Continue Reading

References

Sep 1, 1992·Antimicrobial Agents and Chemotherapy·M L BarclayS T Chambers
Jan 14, 2003·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nicole BaumertHans-Georg Sahl
Jan 9, 2004·Infectious Disease Clinics of North America·John Turnidge
Jan 17, 2004·Lancet·Philippe Moreillon, Yok-Ai Que
Feb 6, 2004·International Journal of Medical Microbiology : IJMM·Franziska SchaaffHans-Georg Sahl
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Samuel A ShelburneRichard J Hamill
Nov 24, 2004·International Journal of Antimicrobial Agents·Wendy J MunckhofJohn D Turnidge
Mar 16, 2005·Pharmacotherapy·Michael J Rybak, Kerry L LaPlante
Apr 9, 2005·The New England Journal of Medicine·Scott K FridkinUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
Apr 28, 2005·The Lancet Infectious Diseases·Nicola ZetolaWilliam R Bishai
Mar 17, 2006·Nature Reviews. Microbiology·Richard A ProctorGeorg Peters
May 17, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G KahlmeterO Stetsiouk
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Vincent H TamElizabeth A Coyle
Sep 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Parham SendiWerner Zimmerli
Dec 25, 2007·The Korean journal of laboratory medicine·Heungsup SungGin Hyug Lee

❮ Previous
Next ❯

Software Mentioned

Sigma Stat

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.